Welcome to our dedicated page for CARECLOUD SEC filings (Ticker: CCLDO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CareCloud, Inc. 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock (CCLDO) filings page on Stock Titan is designed to help investors connect the company’s regulatory disclosures with the terms and performance of this preferred security. While no specific SEC filings are listed in the provided data set, CareCloud’s public communications give a clear picture of the types of information that typically appear in its formal reports and offering documents.
For CCLDO, investors generally look to SEC filings such as registration statements, prospectuses, and periodic reports for the full legal description of the Series B Preferred Stock. These documents explain the 8.75% annual dividend rate based on a $25.00 per share liquidation preference, the cumulative nature of dividends, the monthly payment schedule, and the rights of holders in various scenarios. They also detail the issuer’s redemption options, including step-down redemption prices over time and redemption rights upon a Change of Control, as described in CareCloud’s dividend and capital markets announcements.
Company filings also typically provide context on CareCloud’s broader healthcare technology and AI business, including revenue cycle management, practice management, electronic health records, business intelligence, patient experience management, digital health, and AI initiatives. In its earnings releases and financial summaries, CareCloud has discussed revenue trends, profitability, acquisitions such as Medsphere’s hospital IT business and HFMA’s MAP App, and the role of its AI Center of Excellence. These topics are often expanded upon in Forms 10-K and 10-Q, along with risk factors, capital structure details, and discussions of preferred stock dividends and arrears.
On Stock Titan, AI-powered tools can help users interpret complex filing language related to CCLDO. Summaries can highlight key terms of the Series B Preferred Stock, such as dividend rights, redemption mechanics, and priority relative to common stock, as well as draw attention to sections of annual and quarterly reports that discuss preferred dividends, arrears plans, and financing strategies. Investors can also use filing data to cross-reference CareCloud’s press releases about dividend declarations, arrears catch-up plans, and redemption options with the formal terms set out in the Certificate of Designations and other governing documents.
By reviewing CareCloud’s SEC filings alongside its news releases, investors gain a more complete view of how the CCLDO preferred stock fits within the company’s capital structure and how its income features relate to the performance of CareCloud’s healthcare technology and AI platform.
CareCloud, Inc. files its annual report describing its technology-enabled revenue cycle management, cloud software and expanding generative AI solutions for U.S. healthcare providers. The company relies heavily on offshore operations in Pakistan and Sri Lanka, where roughly 3,300 staff support its cost advantage.
As of June 30, 2025, non‑affiliate common equity had an aggregate market value of about $85.1 million, and at March 6, 2026 there were 42,492,949 common shares outstanding. The filing highlights extensive business, cybersecurity, regulatory and macro risks, including past suspension and later resumption of preferred dividends, ongoing arrears, and dilution from a March 2025 conversion of most Series A preferred into common stock.
CareCloud director Lawrence S. Sharnak reported an equity award vesting and share issuance. On February 8, 2026, 7,500 restricted stock units converted into 7,500 shares of CareCloud common stock at a price of $0. According to the filing, these restricted stock units and the resulting shares were granted under the company’s Amended and Restated Equity Incentive Plan without payment by Sharnak.
Following the transaction, Sharnak directly owned 127,750 shares of common stock and 26,250 restricted stock units. This reflects routine compensation-related activity rather than an open-market purchase or sale.
CareCloud, Inc. director Cameron Munter reported a routine equity compensation vesting. On February 8, 2026, 7,500 restricted stock units converted into 7,500 shares of common stock at a price of $0 per share, under the company’s Amended and Restated Equity Incentive Plan.
After this conversion, Munter directly beneficially owned 202,750 shares of CareCloud common stock and 26,250 restricted stock units. The transaction involved no cash payment by the reporting person and reflects standard compensation-based vesting rather than an open‑market purchase or sale.
CareCloud, Inc. director Anne Busquet reported the vesting and conversion of 7,500 restricted stock units into common stock on February 8, 2026. The RSUs and resulting shares were issued under the company’s Amended and Restated Equity Incentive Plan without any cash payment by her.
After this equity award vesting, she directly holds 295,138 shares of CareCloud common stock and 26,250 derivative securities in the form of restricted stock units.
CareCloud, Inc. director Bill Korn reported the vesting and conversion of 7,500 restricted stock units into common stock on February 8, 2026. The RSUs and resulting shares were issued under the company’s Amended and Restated Equity Incentive Plan without any cash payment by Korn.
After this transaction, Korn beneficially owns 211,633 shares of CareCloud common stock directly and 26,250 restricted stock units, reflecting his ongoing equity-based compensation as a director.
CareCloud, Inc. director Bill Korn reported the vesting of equity awards and related share issuance. On January 31, 2026, 6,250 restricted stock units converted into 6,250 shares of common stock at a price of $0.00 under the company’s Amended and Restated Equity Incentive Plan, without payment by Korn. Following this transaction, he directly owned 204,133 shares of common stock and 33,750 restricted stock units.
CareCloud, Inc. director Anne Busquet reported a routine equity award vesting and conversion. On January 31, 2026, 6,250 restricted stock units vested and converted into 6,250 shares of common stock at a price of $0.00 under the company’s Amended and Restated Equity Incentive Plan, without payment by Busquet.
After this transaction, she directly holds 287,638 shares of common stock and 33,750 restricted stock units, reflecting ongoing participation in CareCloud’s long‑term incentive program rather than an open‑market purchase or sale.
CareCloud director Lawrence Steven Sharnak reported the vesting of equity awards and related share issuance. On January 31, 2026, 6,250 restricted stock units converted into 6,250 shares of CareCloud common stock at a price of $0 per share under the company’s Amended and Restated Equity Incentive Plan.
After this transaction, Sharnak directly owned 120,250 shares of common stock and 33,750 restricted stock units. The award vested without cash payment by the reporting person, reflecting compensation delivered in company equity rather than cash.
CareCloud, Inc. director Cameron Munter reported the vesting and conversion of restricted stock units into common stock. On January 31, 2026, 6,250 restricted stock units converted into 6,250 shares of common stock at a price of $0.00 under CareCloud’s Amended and Restated Equity Incentive Plan, without payment by Munter.
After this transaction, Munter directly owned 195,250 shares of CareCloud common stock and 33,750 restricted stock units. The filing reflects equity-based compensation vesting rather than an open‑market purchase or sale.
CareCloud, Inc. furnished an update stating that its Board of Directors has declared monthly cash dividends on its Series A and Series B Cumulative Redeemable Perpetual Preferred Stock. These dividends are scheduled for payment in February, March and April 2026, providing continued cash distributions to holders of these preferred shares during that period. Further details, including the specific dividend terms, are contained in a press release dated January 20, 2026 that is incorporated by reference as an exhibit.